HMHenna Martiskainen

Henna Martiskainen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henna Martiskainen has a total of 348 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

    by Jesper Qvist Thomassen, Hampton Leonard, Brittany Ulms, Benjamin Grenier-Boley, Sami Heikkinen, Pablo Garcia-González, Atahualapa Castillo-Morales, Masataka Kikuchi, Jungsoo Gim, Han Cao, et al.


  • Open Access

    PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures

    by Audrey Coulon, Florian Rabiller, Mari Takalo, Avishek Roy, Alexandre Pelletier, Henna Martiskainen, Dolores Siedlecki-Wullich, Nina Lannette-Weimann, Naďa Majerníková, Arthur Grenon, et al.


  • Open Access

    Lithium chloride alters Tau phosphorylation, kinase activity, and Rho GTPase signaling in cell models

    by Dorit Hoffmann, Virpi Ahola, Nadine Huber, Teemu Natunen, Stina Leskelä, Mari Takalo, Henna Martiskainen, Stephanie Ballweg, Egor Vorontsov, Stefan Selzer, et al.


  • Open Access

    Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers

    by Heli Jeskanen, Sami Heikkinen, Inka Kervinen, Jenni Lehtisalo, Tiia Ngandu, Roosa-Maria Willman, Jessica Rosa, Dorit Hoffmann, Finn Gen, Ville Leinonen, et al.

    Background: The PLCG2 -P522R variant, which encodes a mildly hyperactive form of the PLCγ2 enzyme, has been identified as a protective genetic factor against Alzheimer’s disease (AD). Many recently discovered AD-associated microglial risk genes converge on the TREM2-PLCγ2 signaling pathway, emphasizing the importance of characterizing this signaling pathway to uncover potential therapeutic targets and biomarkers. In this study, we investigated the effects of AD-associated PLCG2 and TREM2 variants, particularly in individuals carrying the APOE ε4 allele, and explored plasma biomarker profiles associated with these variants. Methods: Using genotype and clinical endpoint data from the FinnGen genomic research project, we conducted Kaplan–Meier survival analyses and Cox proportional hazards models to assess the ages of onset for AD, anxiety, and type 2 diabetes. The key findings were replicated in the UK Biobank datasets. Additionally, we assessed several metabolic and inflammatory plasma biomarkers in relation to PLCG2 and TREM2 variants among participants in the FINGER multi-domain lifestyle intervention cohort. Results: In FinnGen, both the PLCG2 -P522R and PLCG2 -3’UTR variants associated independently with a delayed age of AD onset, including among heterozygous APOE ε4 carriers. Also, carriers of the PLCG2 -P522R variant showed significantly elevated plasma levels of ghrelin. Conversely, APOE ε4 carriers with the TREM2-R62H variant exhibited an earlier AD onset age. Similar trends for AD onset age were observed in the UK Biobank data. Conclusions: These findings indicate that protective PLCG2 variants may mitigate APOE ε4-associated AD risk in the Finnish population. Moreover, the elevated plasma ghrelin levels observed in the carriers of the PLCG2 -P522R variant suggest a potential connection between this metabolic hormone and beneficial anti-inflammatory or cognitive effects, although its specific role in AD remains uncertain. Collectively, our results highlight the need for additional studies to further elucidate the mechanisms and biomarkers through which protective PLCG2 variants interact with APOE ε4.


  • Open Access

    The protective PLCG2 variants delay Alzheimer’s disease onset age in APOE ε 4 carriers

    by Heli Jeskanen, Sami Heikkinen, Inka Kervinen, Jenni Lehtisalo, Tiia Ngandu, Roosa-Maria Willman, Jessica Rosa, Dorit Hoffmann, Finn Gen, Ville Leinonen, et al.

    INTRODUCTION: We investigated the impact of protective PLCG2 -P522R and PLCG2 -3’UTR variants, and the TREM2 -R62H risk variant on Alzheimer’s disease (AD) onset age in relation to APOE ε4 status. Plasma-based biomarkers of the different variants were also explored. METHODS: Kaplan-Meier and survival analyses were performed using FinnGen genotype and clinical endpoint data to assess the onset ages of AD, anxiety, and type 2 diabetes. Plasma biomarkers related to metabolism and inflammation were analyzed in 145 FINGER cohort participants. RESULTS: PLCG2 -P522R and PLCG2 -3’UTR variants delayed AD onset, including among APOE ε 4 carriers. PLCG2 -P522R carriers showed elevated plasma ghrelin levels. TREM2 -R62H variant associated with an earlier onset of AD in APOE ε 4 carriers. DISCUSSION: Protective PLCG2 variants may mitigate APOE ε 4-mediated risk of AD, which coincide with increased plasma levels of ghrelin. These findings highlight the further need to explore biomarkers and mechanisms associated with the protective variants in relation to APOE ε 4.

  • Open Access

    APOE stratified genome-wide association studies provide novel insights into the genetic etiology of Alzheimers’s disease

    by Jesper Qvist Thomassen, Hampton Leonard, Brittany Ulms, Benjamin Grenier-Boley, Sami Heikkinen, Pablo Garcia-González, Atahualapa Castillo-Morales, Masataka Kikuchi, Jungsoo Gim, Han Cao, et al.

    Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.


  • Open Access

    Monoallelic TYROBP deletion is a novel risk factor for Alzheimer’s disease

    by Henna Martiskainen, Roosa-Maria Willman, Päivi Harju, Sami Heikkinen, Mette Heiskanen, Stephan A. Müller, Rosa Sinisalo, Mari Takalo, Petra Mäkinen, Teemu Kuulasmaa, et al.

    Biallelic loss-of-function variants in TYROBP and TREM2 cause autosomal recessive presenile dementia with bone cysts known as Nasu-Hakola disease (NHD, alternatively polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, PLOSL). Some other TREM2 variants contribute to the risk of Alzheimer’s disease (AD) and frontotemporal dementia, while deleterious TYROBP variants are globally extremely rare and their role in neurodegenerative diseases remains unclear. The population history of Finns has favored the enrichment of deleterious founder mutations, including a 5.2 kb deletion encompassing exons 1–4 of TYROBP and causing NHD in homozygous carriers. We used here a proxy marker to identify monoallelic TYROBP deletion carriers in the Finnish biobank study FinnGen combining genome and health registry data of 520,210 Finns. We show that monoallelic TYROBP deletion associates with an increased risk and earlier onset age of AD and dementia when compared to noncarriers. In addition, we present the first reported case of a monoallelic TYROBP deletion carrier with NHD-type bone cysts. Mechanistically, monoallelic TYROBP deletion leads to decreased levels of DAP12 protein (encoded by TYROBP) in myeloid cells. Using transcriptomic and proteomic analyses of human monocyte-derived microglia-like cells, we show that upon lipopolysaccharide stimulation monoallelic TYROBP deletion leads to the upregulation of the inflammatory response and downregulation of the unfolded protein response when compared to cells with two functional copies of TYROBP. Collectively, our findings indicate TYROBP deletion as a novel risk factor for AD and suggest specific pathways for therapeutic targeting.


  • Open Access

    C9orf72 repeat expansion-carrying iPSC-microglia from FTD patients show increased phagocytic activity concomitantly with decreased number of autophagosomal-lysosomal vesicles

    by Hannah Rostalski, Tomi Hietanen, Dorit Hoffmann, Sami Heikkinen, Nadine Huber, Ashutosh Dhingra, Salvador Rodriguez-Nieto, Teemu Kuulasmaa, Sohvi Ohtonen, Henna Jäntti, et al.

    C9orf72 hexanucleotide repeat expansion (HRE) is a major genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. The role of microglia in these C9orf72 HRE-associated diseases is understudied. To elucidate effects of C9orf72 HRE on microglia, we have characterized human induced pluripotent stem cell-derived microglia (iMG) from behavioral variant frontotemporal dementia (bvFTD) patients carrying the C9orf72 HRE. C9orf72 HRE iMG were compared to iMG from healthy controls and sporadic bvFTD patients. The phenotypes of iMG were analyzed using bulk RNA sequencing, biochemical and immunofluorescence analyses, and live cell imaging. C9orf72 HRE-carrying iMG showed nuclear RNA foci and poly-GP dipeptide repeat proteins but no decreased C9orf72 mRNA or protein expression. TDP-43 pathology was absent from all bvFTD iMG. As compared to healthy control iMG, quantitative immunofluorescence analyses indicated that all bvFTD iMG had reduced number, size, and intensity of LAMP2-A-positive vesicles. C9orf72 HRE-carrying iMG additionally showed decreased number, size, and intensity of p62/SQSTM1-positive vesicles. These changes were accompanied by increased phagocytic activity of the C9orf72 HRE-carrying iMG. Serum starvation increased phagocytic activity also in the iMG of sporadic bvFTD patients. RNA sequencing revealed that iMG of C9orf72 HRE-carrying bvFTD patients as compared to the iMG of sporadic bvFTD patients showed differential gene expression in pathways related to RNA and protein regulation and mitochondrial metabolism. Our data suggest potential alterations in the autophagosomal/lysosomal pathways in bvFTD patient iMG, which are further reinforced by the C9orf72 HRE and functionally manifest as increased phagocytic activity.


  • Open Access

    Neuronal downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease hallmarks

    by Jean-Charles Lambert, Audrey Coulon, Florian Rabiller, Mari Takalo, Avishek Roy, Henna Martiskainen, Dolores Siedlecki-Wullich, Tiago Mendes, Celia Lemeu, Lukas-Iohan Carvalho, et al.

    We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may impair synaptic mechanisms in rat primary neuronal cultures. Out of the gene targets identified, we found that shRNA-mediated downregulation of Plcg2 in mouse dentate gyrus neurons consistently impaired dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and was associated with increased levels of Aβ and Tau phosphorylation, potentially via the AKT/GSK3β axis. Very rare PLCG2 loss-of-functon(LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLCγ2 levels, consistent with nonsense-mediated mRNA decay mechanisms. Restoring PLCγ2 levels in shPLCG2-hNCs fully reversed the disease-related phenotypes. Our findings indicate that the downregulation of PLCγ2 increases the risk of AD by impairing synaptic function and increasing the levels of Aβ and Tau phosphorylation in neurons.

  • Open Access

    Monoallelic TYROBP deletion is a novel risk factor for Alzheimer’s disease

    by Henna Martiskainen, Roosa-Maria Willman, Sami Heikkinen, Stephan A. Müller, Rosa Sinisalo, Mari Takalo, Petra Mäkinen, Teemu Kuulasmaa, Viivi Pekkala, Ana Galván del Rey, et al.

    Biallelic loss-of-function variants in TYROBP and TREM2 cause autosomal recessive presenile dementia with bone cysts known as Nasu-Hakola disease (NHD, alternatively polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, PLOSL). Some other TREM2 variants contribute to the risk of Alzheimer’s disease (AD) and frontotemporal dementia, while deleterious TYROBP variants are globally extremely rare and their role in neurodegenerative diseases remains unclear. The population history of Finns has favored the enrichment of deleterious founder mutations, including a 5.2 kb deletion encompassing exons 1-4 of TYROBP and causing NHD in homozygous carriers. We used here a proxy marker to identify monoallelic TYROBP deletion carriers in the Finnish biobank study FinnGen combining genome and health registry data of 520,210 Finns. We show that monoallelic TYROBP deletion associates with an increased risk and earlier onset age of AD and dementia when compared to noncarriers. In addition, we present the first reported case of a monoallelic TYROBP deletion carrier with NHD-type bone cysts. Mechanistically, monoallelic TYROBP deletion leads to decreased levels of DAP12 protein (encoded by TYROBP ) in myeloid cells. Using transcriptomic and proteomic analyses of human monocyte-derived microglia-like cells, we show that upon lipopolysaccharide stimulation monoallelic TYROBP deletion leads to the upregulation of the inflammatory response and downregulation of the unfolded protein response when compared to cells with two functional copies of TYROBP . Collectively, our findings indicate TYROBP deletion as a novel risk factor for AD and suggest specific pathways for therapeutic targeting. One Sentence Summary: Nasu-Hakola disease causing TYROBP deletion increases the risk of Alzheimer’s disease in elderly monoallelic carriers in the Finnish population.